الفهرس 
Effect of celebrex pre-medication on the intra and post-treatment endodontic pain in teeth with symptomatic irreversible pulpitis : Double blind randomized clinical trial
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
The aim of the study: to assess the efficacy of Celebrex as premedication in controlling intra-operative and post-endodontic pain after single visit endodontic treatment of mandibular molar teeth with symptomatic irreversible pulpitis. Methods: Forty-six patients, aged 18-40 years with no gender predilection, diagnosed with symptomatic irreversible pulpitis in mandibular molars were included in the study. Patients were actively experiencing moderate to severe pain associated with prolonged response to cold testing with ethyl chloride spray. Patients were randomly assigned into two groups, each consisted of 23 patients: {u2022}Celebrex (experimental) group: patients received 200mg capsule 1 hour prior to endodontic treatment {u2022}Placebo (control) group: patients received all-purpose flour capsule 1 hour prior to endodontic treatment. After 60 minutes of administrating the premedication, the patient received 3.6 ml standard IANB with 2% mepivacaine containing 1:1200,000 levonordefrin. After 15 minutes, lip numbness and the tooth was tested with cold spray and the patients were asked to record their pain on VAS prior to initiation of treatment. Access cavity preparation was performed, followed by initial negotiation and extirpation of the pulpal tissues, and if the patient felt pain at any of the previous stages the treatment was stopped, the pain intensity was recorded (intra-operative pain) and supplemental anesthesia was administrated either in the form of long buccal infiltration or intra-pulpal anesthesia depending on the stage of treatment to augment the IANB anesthesia